Navigation Links
Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
Date:4/9/2008

tion occurred in 22% of patients. The reasons for discontinuation included peripheral neuropathy (8%), asthenic conditions (3%) and thrombocytopenia and diarrhea (each 2%). In total, 2% of the patients died and the cause of death was considered by the investigator to be possibly related to study drug: including reports of cardiac arrest, congestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. This integrated analysis does not include the Phase 3, VELCADE plus DOXIL study.

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. Millennium's website is http://www.millennium.com. Millennium has announced that it has entered into an Agreement and Plan of Merger, dated as of April 10, 2008, with Takeda America Holdings, Inc., a New York corporation ("Takeda"), and Mahogany Acquisition Corp., a Delaware corporation and a wholly-owned subsidiary of Takeda ("Merger Sub"), pursuant to which Merger Sub will make a cash tender offer (the "Offer") to purchase all of the issued and outstanding shares of Millennium common stock, and Millennium will become a wholly-owned subsidiary of Takeda.

Use of Forward-Looking Statements

This material contains "forward-looking statements" that involve significant risks and uncer
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Millennium Announces $200,000 Purchase Order From Greek Distributor
2. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
3. Millennium Over-Delivers on 2007 Goals and Financial Guidance
4. Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market
5. Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results
6. Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection
7. Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order
8. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
9. Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market
10. Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
11. Millennium to Webcast Third-Quarter 2007 Financial and Operational Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... (PRWEB) August 20, 2014 Not long ... E&L studies should be performed late in the development ... known. But current regulatory trends suggest that, like many ... the rise. In recent years, multiple drug sponsors have ... or address specific questions during phase I/II. It’s not ...
(Date:8/20/2014)... Aug. 20, 2014 /PRNewswire-iReach/ -- A case study ... between the school,s bioengineering department and the Intel® ... Intel® Software Academic Program, UCSD,s research focuses on ... human body.  Photo - ... the work of Dr. Todd P. Coleman ...
(Date:8/20/2014)... improve the health of your heart, researchers have discovered. ... a standard TENS machine like those designed to relieve ... the small raised flap at the front of the ... The stimulation changed the influence of the nervous system ... can drive failing hearts too hard. , Professor Jim ...
(Date:8/20/2014)... WriteResult®, a leading provider of Electronic Patient ... its myPROpad™ ePRO tablet with the addition of a ... most widely used and well-respected Patient Reported Outcome (PRO) ... is used during clinical trials and in other health ... used to demonstrate Health-Related Quality of Life outcomes (HRQoL) ...
Breaking Biology Technology:Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2'Tickling' your ear could be good for your heart 2EQ-5D™ Assessment Now Available for iPad 2
... Oct. 28 BioStorage Technologies, a global leader ... storage for the pharmaceutical and biotechnology industries, announces ... of global sales.   Atwood will ... and leadership of global sales initiatives. His key ...
... Calif., Oct. 28 ChromaDex Corporation (OTC Bulletin Board: ... of phytochemical and botanical reference standards and the creation ... appointed William F. Spengler to President of the Company, ... and diversified background to the position, having held leadership ...
... (Nasdaq: UTHR ) today announced its results of operations ... for the third quarter of 2010 were $171.0 million, up from ... the third quarter of 2010 was $39.7 million, or $0.70 per ... per basic share, for the same quarter in 2009. Gross margin ...
Cached Biology Technology:BioStorage Technologies Appoints New Vice President of Global Sales 2ChromaDex Names Pharmaceutical Industry Veteran William F. Spengler as President 2ChromaDex Names Pharmaceutical Industry Veteran William F. Spengler as President 3United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 2United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 3United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 4United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 5United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 6United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 7
(Date:8/19/2014)... New Rochelle, August 19, 2014A new ovoid structure discovered ... iron-rich clay, contains a variety of minerals, and shows ... with resulting melting of the permafrost and mixing of ... a broad range of analytical studies to determine the ... hypotheses for how this ovoid formed, point to the ...
(Date:8/19/2014)... pain, but its effect on pain following brachial ... study reported on the Neural Regeneration Research ... of an avulsion injury to the left brachial ... were given electroacupuncture stimulation at bilateral Quchi (LI11), ... electroacupuncture therapy, chronic neuropathic pain in the rats, ...
(Date:8/19/2014)... 2014 Smart Technology Sector improves ... as latest developments, ad campaigns and partnerships are announced: ... EBAY ), Amazon.com Inc. (NASDAQ: AMZN ), ... (NASDAQ: GOOG ) and Mastercard Incorporated (NYSE: ... authentication company focused on the growing m-commerce market releases ...
Breaking Biology News(10 mins):Life on Mars? Implications of a newly discovered mineral-rich structure 2Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 2Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 3Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 4Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 5Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 6Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 7
... bathrooms may become a thing of the past with new ... at the University of New South Wales are developing new ... hospitals and the home. , Led by Professor ... for Functional Nanomaterials, a research team is studying tiny particles ...
... have made nisin, a natural antibiotic used for more than ... the first time using nature's toolbox. They also identified the ... its unique biological power. , The work -- published in ... the almost magical manner in which nisin is made in ...
... of malaria up to five months in advance has been developed ... uses predictions of climate variability to indicate the level of risk ... peak malaria season ?the earliest point at which predictions have ever ... providers in preventing and controlling the disease. , Malaria ...
Cached Biology News:Creation of antibiotic in test tube holds promise for better antibiotics 2Scientists develop malaria forecasting tool to predict disease risk 2
... tissue panels are designed for studying ... or proteins of interest in different ... positively charged glass slides. Total RNA ... identical format, and cDNA from those ...
Total Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
Total Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
... The T2-02 diaphragm pump features T ... and achieves remarkable performance and efficiency. With ... performance range, T2-02 is ideal for use ... Offers ultra-compact size, long life, and high ...
Biology Products: